Background: Pragmatic trials comparing standard-of-care interventions may improve the quality of care for future patients, but raise ethical questions about limitations on decisional autonomy. We sought to understand how patients and physicians view and respond to these questions in the contexts of pragmatic trials and of usual clinical care. Methods: We conducted scenario-based, semistructured interviews with 32 patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis in outpatient dialysis units and with 24 nephrologists. Each participant was presented with two hypothetical scenarios in which a protocolized approach to hemodialysis treatment time was adopted for the entire dialysis unit as part of a clinical trial or a new clinical practice. Results: A modified grounded theory analysis revealed three major themes: (1) the value of research, (2) the effect of protocolized care on patient and physician autonomy, and (3) information exchange between patients and physicians, including the mechanism of consent. Most patients and physicians were willing to relinquish decisional autonomy and were more willing to relinquish autonomy for research purposes than in clinical care. Patients’ concerns toward clinical trials were tempered by their desires for certainty for a positive outcome and for physician validation. Patients tended to believe that being informed about research was more important than the actual mechanism of consent, and most were content with being able to opt out from participating. Conclusions: This qualitative study suggests the general acceptability of a pragmatic clinical trial comparing standard-of-care interventions that limits decisional autonomy for nephrologists and patients receiving hemodialysis. Future studies are needed to determine whether similar findings would emerge among other patients and providers considering other standard-of-care trials.
This editorial appears in the March 2025 issue of the American Journal of Bioethics. Introduction The rush to deploy artificial intelligence (AI) and machine learning (ML) systems in medicine highlights the need for bioethics to deepen its normative engagement in disentangling autonomy from beneficence and justice in responsible medical practice. One of the reasons that informed […]
This editorial appears in the March 2025 issue of the American Journal of Bioethics. As Hurley and colleagues note in this issue of the Journal, transparency in healthcare supports informed patient decision making, promotes trust in healthcare professionals, and encourages patients to learn more about their care. Those who reject transparency do so at great risk, […]
Neuroimaging technologies such as the electroencephalogram (EEG) have been utilized to predict intelligence quotients (IQ) across various populations. Ethical analyses should examine whether the use of these methods, which purport to establish a biological basis for intelligence are potentially harmful and stigmatizing. Research that aims to evaluate whether there is a biological basis for differences in […]
This editorial appears in the February 2025 issue of the American Journal of Bioethics. In this issue, Chapman et al. recommend large changes to Institutional Review Boards (IRBs) to address group harms in research. We agree with the concerns underlying their recommendations. Researchers have a responsibility to foresee and prevent group harms from arising out of their […]
We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Privacy Policy. By closing this message, you are consenting to our use of cookies.